Interferon-free combo Faldaprevir and Deleobuvir with ribavirin achieves 95% cure rate in geno 1b
mallani said
Jun 23, 2013
Hi Jill,
I don't know about you, but my head is starting to spin with the new DAA's. I obviously don't understand, but why are we looking at drug combos that are useful in Geno 1b but not 1a? In the USA, about 60% of HCV patients have Geno 1a as opposed to only 17% who have Geno 1b. I also don't understand why studies are done on drugs that still require a favorable Interleukin 28B allele (CC). Antiproteases cause problems because they block some other protease sites in the body, not just in the HCV. Incivek is out of favour due to the deaths from rashes and Victrelis sales have soared. If antiproteases must be used, why not stick with Victrelis which now has been used extensively. By using a NS5A blocker, the problem of IL28B status is removed, as this is the viral site responsible for Interferon sensitivity( and possibly Riba).
To my simple mind, Boehringer- Ingelheim are just wasting their money and making it more difficult for us to follow the real DAA contenders.
Cinnamon Girl said
Jun 17, 2013
Faldaprevir and deleobuvir with ribavirin achieves 95% cure rate in geno 1b
Interferon-free combo faldaprevir+ and deleobuvir+ (BI 207127)/ribavirin achieves 95% viral cure rates in genotype-1b hepatitis C patients
New data from Boehringer Ingelheim`s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV), one of the most common types of HCV globally.
Hi Jill,
I don't know about you, but my head is starting to spin with the new DAA's. I obviously don't understand, but why are we looking at drug combos that are useful in Geno 1b but not 1a? In the USA, about 60% of HCV patients have Geno 1a as opposed to only 17% who have Geno 1b. I also don't understand why studies are done on drugs that still require a favorable Interleukin 28B allele (CC). Antiproteases cause problems because they block some other protease sites in the body, not just in the HCV. Incivek is out of favour due to the deaths from rashes and Victrelis sales have soared. If antiproteases must be used, why not stick with Victrelis which now has been used extensively. By using a NS5A blocker, the problem of IL28B status is removed, as this is the viral site responsible for Interferon sensitivity( and possibly Riba).
To my simple mind, Boehringer- Ingelheim are just wasting their money and making it more difficult for us to follow the real DAA contenders.
Faldaprevir and deleobuvir with ribavirin achieves 95% cure rate in geno 1b
Interferon-free combo faldaprevir+ and deleobuvir+ (BI 207127)/ribavirin achieves 95% viral cure rates in genotype-1b hepatitis C patients
New data from Boehringer Ingelheim`s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV), one of the most common types of HCV globally.
http://www.hepctrust.org.uk/News_Resources/news/2013/June/Faldaprevir+and+deleobuvir+achieves+95+cure+rate+in+geno+1b